{"id":"spm-927","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Ataxia"}]},"_chembl":{"chemblId":"CHEMBL5955070","moleculeType":null,"molecularWeight":"514.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SPM 927 selectively inhibits T-type calcium channels, which are involved in the generation and propagation of seizures. By blocking these channels, the drug reduces abnormal neuronal firing and is being developed as an anti-seizure medication. T-type calcium channel blockade represents a distinct mechanism from many existing antiepileptic drugs.","oneSentence":"SPM 927 is a selective T-type calcium channel blocker that reduces neuronal excitability and seizure activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:20.090Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (focal seizures)"},{"name":"Generalized seizures"}]},"trialDetails":[{"nctId":"NCT00800215","phase":"PHASE2","title":"A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-03-04","conditions":"Epilepsy","enrollment":60},{"nctId":"NCT00861068","phase":"PHASE2","title":"A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-02","conditions":"Postherpetic Neuralgia","enrollment":44},{"nctId":"NCT00861042","phase":"PHASE2","title":"An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-04","conditions":"Painful Diabetic Neuropathy","enrollment":69},{"nctId":"NCT00220337","phase":"PHASE3","title":"A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-12-21","conditions":"Painful Diabetic Neuropathy","enrollment":371},{"nctId":"NCT02582866","phase":"PHASE3","title":"A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2016-01","conditions":"Epilepsy","enrollment":106},{"nctId":"NCT02477839","phase":"PHASE3","title":"Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2015-06-05","conditions":"Epilepsy With Partial-onset Seizures","enrollment":255},{"nctId":"NCT01432171","phase":"NA","title":"Lacosamide in Preventing Seizures in Participants With Malignant Glioma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-07-25","conditions":"Malignant Glioma","enrollment":37},{"nctId":"NCT00522275","phase":"PHASE3","title":"Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2004-10","conditions":"Partial Epilepsies","enrollment":308},{"nctId":"NCT01484977","phase":"PHASE3","title":"eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-12","conditions":"Epilepsy","enrollment":120},{"nctId":"NCT00552305","phase":"PHASE2","title":"To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2001-08","conditions":"Partial Epilepsies","enrollment":370},{"nctId":"NCT00955357","phase":"PHASE4","title":"Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-08","conditions":"Partial Epilepsies","enrollment":461},{"nctId":"NCT00235443","phase":"PHASE2, PHASE3","title":"A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-09","conditions":"Diabetic Neuropathy","enrollment":451},{"nctId":"NCT00515619","phase":"PHASE3","title":"Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-12","conditions":"Epilepsy","enrollment":376},{"nctId":"NCT00237458","phase":"PHASE2","title":"An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2001-05","conditions":"Chronic Refractory Neuropathic Pain","enrollment":7},{"nctId":"NCT01796938","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2004-06","conditions":"Healthy, Renal Impairment","enrollment":40},{"nctId":"NCT00861445","phase":"PHASE2","title":"A Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic Neuropathy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2001-06","conditions":"Painful Diabetic Neuropathy","enrollment":119},{"nctId":"NCT00235469","phase":"PHASE2, PHASE3","title":"A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-04","conditions":"Diabetic Neuropathy","enrollment":496},{"nctId":"NCT00136019","phase":"PHASE3","title":"SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-03","conditions":"Epilepsy","enrollment":400},{"nctId":"NCT00238524","phase":"PHASE3","title":"A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-12","conditions":"Diabetic Neuropathy","enrollment":357},{"nctId":"NCT00220415","phase":"PHASE3","title":"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-05","conditions":"Partial Seizures With or Without Secondary Generalization","enrollment":""},{"nctId":"NCT00151879","phase":"PHASE2, PHASE3","title":"Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-02","conditions":"Epilepsies, Partial","enrollment":160},{"nctId":"NCT00238511","phase":"PHASE2","title":"An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-11","conditions":"Postherpetic Neuralgia","enrollment":""},{"nctId":"NCT00135109","phase":"PHASE3","title":"Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-10","conditions":"Diabetic Neuropathies","enrollment":654}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BRADYCARDIA"},{"count":1,"reaction":"CONVULSION"},{"count":1,"reaction":"HYPOTENSION"},{"count":1,"reaction":"SOPOR"},{"count":1,"reaction":"SUICIDE ATTEMPT"}],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SPM 927","genericName":"SPM 927","companyName":"UCB Pharma","companyId":"ucb-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPM 927 is a selective T-type calcium channel blocker that reduces neuronal excitability and seizure activity. Used for Epilepsy (focal seizures), Generalized seizures.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}